Combining the best of UV, ozone, peroxide and chemical oxidation technologies the system obviates biocide and chemical treatment of manufacturing or healthcare fluid waste
The unique design of the TPR4000 includes a negatively-charged cathode at the core of the apparatus with electrode pins protruding out toward an outside, positively-charged anode cylinder wall and is spun at 1000 rpm
Symbios Technologies, a developer of dynamic aqueous plasma technology platforms, is commercialising its Tubular Plasma Reactor (TPR4000) advanced plasma oxidation system for fluid treatment in manufacturing, healthcare, utility, and oil and gas vertical markets.
Justin Bzdek, president and CEO, Symbios, said: 'The TPR is the first of its kind multi-modal oxidation system that combines electricity and air to achieve both hydrogen- and oxygen-based oxidation chemistries, without added chemicals.'
Through non-thermal, homogeneous, distributed plasma discharge directly in water via its patented, groundbreaking design, the TPR4000 achieves rapid disinfection and reduction of BOD and COD with superior efficacy and lower cost vs. other advanced oxidation processes, without waste streams.
Combining the best of UV, ozone, peroxide, and chemical oxidation technologies, the Symbios TPR technology has been tested for efficacy in the food & beverage, healthcare, power plant, and other industrial and municipal applications.
Symbios Technologies’ modular reactor is low in capital cost, able to replace existing energy-hungry or poor-performing advanced oxidation processes, reduce or eliminate the use of biocides, reduce or eliminate chemical additives, and reduce the overall maintenance cost of water treatment systems, in particular extending the life and reducing fouling of membranes.
The company has been promoting the system at Water Environment Federation Technical Exhibition and Conference (WEFTEC), in the National Science Foundation (NSF) Small Business Innovation Research (SBIR) Program Pavilion, (24 - 28 September, New Orleans, LA).
The Symbios TPR4000 is being advanced under Phase II and Phase IIB supplement NSF SBIR grants along with other grants and industry investment.
'The NSF’s support of science and technology startups with non-dilutive grants through the SBIR program is critical to the success innovative companies like Symbios,' said Bzdek.